Communiqués Citius Pharmaceuticals, Inc.

Actions

CTXR

US17322U3068

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
0,5786 ^USD	+1,47%		-3,57%	-25,53%

14/08	Citius Oncology, Inc. annonce la nomination de Jonathan Peri, Ph.D., J.D., en tant qu'administrateur indépendant, à compter du 10 août 2026	CI
14/08	Citius Pharmaceuticals, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 juin 2026	CI

Communiqués

12/08	Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri	PR
26/05	Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting	PR
15/05	Citius Pharmaceuticals : Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update	PU
15/05	Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update	PR
27/04	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules	AQ
16/02	Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR	AQ
16/10/25	Citius Pharmaceuticals (NASDAQ: CTXR) Eyes $400M Market Opportunity with LYMPHIR Launch	AQ
22/08/25	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch	PR
12/08/25	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update	PR
17/07/25	Citius Oncology Announces Closing of $9.0 Million Public Offering	PR
16/07/25	Citius Oncology Announces Pricing of $9.0 Million Public Offering	PR
15/07/25	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora	PR
08/07/25	Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement	PR
12/06/25	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules	PR
10/06/25	Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules	PR
14/05/25	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update	PR
05/05/25	Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference	PR
01/04/25	Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock	PR
12/03/25	Citius Pharmaceuticals : Corporate Presentation	PU
17/02/25	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update	AQ
14/02/25	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update	PR
23/01/25	Citius Pharmaceuticals : CTXR Fact Sheet	PU
08/01/25	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules	PR
30/12/24	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update	AQ
27/12/24	Citius Pharmaceuticals : Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Form 8 K	PU